$GOVX Monkeypox Play To Watch
GeoVax Labs, Inc. (NASDAQ: GOVX) is a clinical-stage biotech company with an impressive pipeline of vaccines and immunotherapies targeting cancer and infectious diseases using its proprietary technology platform. After the WHO declared monkeypox spread a global health emergency, monkeypox related stocks surged – with GOVX stock climbing more than 150%. As the company’s technology is viewed as a safe smallpox vaccine, GOVX stock could be on track to continue climbing as the fear of monkeypox continues rising.
GOVX Fundamentals
Monkeypox
With growing fears over the rapid spread of monkeypox, monkeypox related stocks have been gaining more momentum recently as several companies are looking to develop treatments for this disease. One of these plays is GOVX stock which is developing vaccines for cancer, Covid-19, as well as other infectious diseases. While the company has no treatment or vaccine for monkeypox in its pipeline, GOVX is gaining investors’ interest thanks to its proprietary technology platform – MVA-VLP. This platform is able to create vaccine candidates using genetic consequences from viruses. Based on this, GOVX could create vaccines for different types of viruses and diseases.
With this in mind, GOVX has the potential to capitalize on the need for monkeypox vaccines since MVA is approved by the FDA for the prevention of smallpox and monkeypox. On that note, MVA has proven to be safe when demonstrated in more than 120 thousand patients during its initial development as well as its development as a vaccine for smallpox while showing durable vaccine responses. In light of this, GOVX stock soared more than 150% after WHO declared monkeypox spread a global health emergency. Considering that there are more than 16 thousand cases of monkeypox throughout 75 countries, GOVX could be a pioneer in monkeypox vaccines if it utilizes its technology in developing a treatment for this virus.
Covid-19 Vaccines
In the meantime, GOVX has a Covid-19 vaccine for immunocompromised patients and a Covid-19 booster vaccine in phase 2 of clinical trials in its pipeline. These vaccines are based on an MVA vector – COH04S1 – which the company is developing thanks to its agreement with City of Hope. According to this agreement, GOVX was granted the exclusive rights to develop and commercialize COH04S1.
In its vaccine for immunocompromised patients phase 2 trials, GOVX is evaluating the safety of COH04S1 compared to the Pfizer mRNA-based vaccine. Meanwhile, GOVX is enrolling 60 healthy individuals vaccinated with a Covid-19 mRNA vaccine for its phase 2 booster study. Given that biotech stocks usually run on binary events like FDA approvals or clinical trial results, GOVX stock could be one to hold in anticipation of these trials’ results.
Cancer Treatment
Meanwhile, GOVX was able to expand its presence in immuno-oncology thanks to its acquisition of Gedeptin. With this in mind, GOVX has been working to integrate Gedeptin with MVA to introduce tumor associated antigens (TAA) to provoke the immune system to find and identify cancers in the body. Currently, Gedeptin is being evaluated in a phase 1/2 clinical trial in patients with head and neck cancer where this trial is being funded by the FDA under its orphan products clinical trial grants program.
During its phase 1 trials, Gedeptin showed a noticeable effect on tumor volume after a single treatment cycle. As a result, GOVX is bullish that repeat administration of the therapy can treat advanced head and neck cancer. As this treatment could be applied to other types of cancers, GOVX could be poised for major growth once its treatments and vaccines are launched into the market. In light of this, GOVX stock could be one of the most profitable long-term holds since the stock is relatively cheap.
Funding
Considering the number of the company’s ongoing clinical trials, GOVX has been looking to raise funds to advance the treatments in its pipeline. For this reason, GOVX issued 3 million shares to a healthcare-focused institutional investor for $1.65 per share. At the same time, GOVX issued 9 million shares to the same investor at the same share price in a private offering. The company also issued to this investor options to purchase up to 12.1 million shares. Through these offerings, GOVS raised $20 million in gross proceeds which the company intends to accelerate its ongoing clinical trials for Covid-19 vaccines and cancer treatments. Considering these treatments’ potential in revolutionizing Covid-19 vaccines and cancer treatments, GOVX stock could be a bargain at its current PPS for bullish investors.
GOVX Financials
Looking at GOVX’s financials, the company’s assets grew from $11.7 million to $16.8 million mainly due to cash increasing to $16.2 million compared to $11.4 million in the previous quarter. Moreover, the company reduced its liabilities from $7.4 million in Q4 to $5.5 million this quarter. Given that the company is developing its treatments and vaccines, GOVX only reported $81.5 thousand in grant revenues. Meanwhile, the company more than doubled its research and development expenses YOY to $1.3 million compared to $602.7 thousand. Based on this, GOVX reported a net loss of $2.4 million – increasing from $1.5 million in Q4.
Technical Analysis
GOVX stock is currently trading at $1.59 and has supports at 1.4, 1.1, and .63. The stock also shows resistances at 1.8 and 2.3. With monkeypox plays gaining momentum following WHO’s declaration of the virus as a global health emergency, GOVX climbed more than 150% on a high trading volume of 203 million. Given that monkeypox is spreading rapidly, GOVX stock could continue witnessing similar volume in the near future.
GOVX recently broke through its resistance and is continuing to move in pre-market. If the stock continues gaining momentum, GOVX could reach near $2. With this in mind, bullish investors could find entry points on GOVX stock on retests of supports. Since there is a gap on the chart near $.06, GOVX could drop to fill this gap. However, it is worth noting that gaps could take several weeks or months to fill.
In light of GOVX’s impressive run, accumulation is on a steep downward trend thanks to investors taking profit. Meanwhile, the MACD is bullish to the upside. The RSI is holding at 93 indicating that GOVX stock is extremely overbought. Based on this, GOVX could drop to let the RSI regulate – providing dip buy opportunities for bullish investors. GOVX has an OS of 12.5 million and a float of 12.2 million.
GOVX Forecast
As the company is able to create vaccines and treatments for several infectious diseases and cancers using its MVA platform, GOVX could be one of the best biotech stocks to hold onto for the long-term. With this in mind, WHO’s declaration of monkeypox as a global health emergency led to GOVX gaining much momentum – triggering its 150% run. Given that the company’s platform is approved by the FDA for the prevention of smallpox and monkeypox, GOVX appears to be in a prime position to capitalize on the growing demand for monkeypox vaccines. With a number of ongoing trials for Covid-19 vaccines and cancer treatments, GOVX stock could be well-positioned to reach new highs as biotech stocks usually move in binary events like clinical trial results.
GOVX Fundamentals
Monkeypox
With growing fears over the rapid spread of monkeypox, monkeypox related stocks have been gaining more momentum recently as several companies are looking to develop treatments for this disease. One of these plays is GOVX stock which is developing vaccines for cancer, Covid-19, as well as other infectious diseases. While the company has no treatment or vaccine for monkeypox in its pipeline, GOVX is gaining investors’ interest thanks to its proprietary technology platform – MVA-VLP. This platform is able to create vaccine candidates using genetic consequences from viruses. Based on this, GOVX could create vaccines for different types of viruses and diseases.
With this in mind, GOVX has the potential to capitalize on the need for monkeypox vaccines since MVA is approved by the FDA for the prevention of smallpox and monkeypox. On that note, MVA has proven to be safe when demonstrated in more than 120 thousand patients during its initial development as well as its development as a vaccine for smallpox while showing durable vaccine responses. In light of this, GOVX stock soared more than 150% after WHO declared monkeypox spread a global health emergency. Considering that there are more than 16 thousand cases of monkeypox throughout 75 countries, GOVX could be a pioneer in monkeypox vaccines if it utilizes its technology in developing a treatment for this virus.
Covid-19 Vaccines
In the meantime, GOVX has a Covid-19 vaccine for immunocompromised patients and a Covid-19 booster vaccine in phase 2 of clinical trials in its pipeline. These vaccines are based on an MVA vector – COH04S1 – which the company is developing thanks to its agreement with City of Hope. According to this agreement, GOVX was granted the exclusive rights to develop and commercialize COH04S1.
In its vaccine for immunocompromised patients phase 2 trials, GOVX is evaluating the safety of COH04S1 compared to the Pfizer mRNA-based vaccine. Meanwhile, GOVX is enrolling 60 healthy individuals vaccinated with a Covid-19 mRNA vaccine for its phase 2 booster study. Given that biotech stocks usually run on binary events like FDA approvals or clinical trial results, GOVX stock could be one to hold in anticipation of these trials’ results.
Cancer Treatment
Meanwhile, GOVX was able to expand its presence in immuno-oncology thanks to its acquisition of Gedeptin. With this in mind, GOVX has been working to integrate Gedeptin with MVA to introduce tumor associated antigens (TAA) to provoke the immune system to find and identify cancers in the body. Currently, Gedeptin is being evaluated in a phase 1/2 clinical trial in patients with head and neck cancer where this trial is being funded by the FDA under its orphan products clinical trial grants program.
During its phase 1 trials, Gedeptin showed a noticeable effect on tumor volume after a single treatment cycle. As a result, GOVX is bullish that repeat administration of the therapy can treat advanced head and neck cancer. As this treatment could be applied to other types of cancers, GOVX could be poised for major growth once its treatments and vaccines are launched into the market. In light of this, GOVX stock could be one of the most profitable long-term holds since the stock is relatively cheap.
Funding
Considering the number of the company’s ongoing clinical trials, GOVX has been looking to raise funds to advance the treatments in its pipeline. For this reason, GOVX issued 3 million shares to a healthcare-focused institutional investor for $1.65 per share. At the same time, GOVX issued 9 million shares to the same investor at the same share price in a private offering. The company also issued to this investor options to purchase up to 12.1 million shares. Through these offerings, GOVS raised $20 million in gross proceeds which the company intends to accelerate its ongoing clinical trials for Covid-19 vaccines and cancer treatments. Considering these treatments’ potential in revolutionizing Covid-19 vaccines and cancer treatments, GOVX stock could be a bargain at its current PPS for bullish investors.
GOVX Financials
Looking at GOVX’s financials, the company’s assets grew from $11.7 million to $16.8 million mainly due to cash increasing to $16.2 million compared to $11.4 million in the previous quarter. Moreover, the company reduced its liabilities from $7.4 million in Q4 to $5.5 million this quarter. Given that the company is developing its treatments and vaccines, GOVX only reported $81.5 thousand in grant revenues. Meanwhile, the company more than doubled its research and development expenses YOY to $1.3 million compared to $602.7 thousand. Based on this, GOVX reported a net loss of $2.4 million – increasing from $1.5 million in Q4.
Technical Analysis
GOVX stock is currently trading at $1.59 and has supports at 1.4, 1.1, and .63. The stock also shows resistances at 1.8 and 2.3. With monkeypox plays gaining momentum following WHO’s declaration of the virus as a global health emergency, GOVX climbed more than 150% on a high trading volume of 203 million. Given that monkeypox is spreading rapidly, GOVX stock could continue witnessing similar volume in the near future.
GOVX recently broke through its resistance and is continuing to move in pre-market. If the stock continues gaining momentum, GOVX could reach near $2. With this in mind, bullish investors could find entry points on GOVX stock on retests of supports. Since there is a gap on the chart near $.06, GOVX could drop to fill this gap. However, it is worth noting that gaps could take several weeks or months to fill.
In light of GOVX’s impressive run, accumulation is on a steep downward trend thanks to investors taking profit. Meanwhile, the MACD is bullish to the upside. The RSI is holding at 93 indicating that GOVX stock is extremely overbought. Based on this, GOVX could drop to let the RSI regulate – providing dip buy opportunities for bullish investors. GOVX has an OS of 12.5 million and a float of 12.2 million.
GOVX Forecast
As the company is able to create vaccines and treatments for several infectious diseases and cancers using its MVA platform, GOVX could be one of the best biotech stocks to hold onto for the long-term. With this in mind, WHO’s declaration of monkeypox as a global health emergency led to GOVX gaining much momentum – triggering its 150% run. Given that the company’s platform is approved by the FDA for the prevention of smallpox and monkeypox, GOVX appears to be in a prime position to capitalize on the growing demand for monkeypox vaccines. With a number of ongoing trials for Covid-19 vaccines and cancer treatments, GOVX stock could be well-positioned to reach new highs as biotech stocks usually move in binary events like clinical trial results.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.